Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB) CEO to participate in a panel discussion at Cowen 44th Annual Health Care Conference. The event will be webcasted and archived for 21 days.
02/27/2024 - 07:00 AM
CAMBRIDGE, Mass. --(BUSINESS WIRE)--
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. ET.
An audio webcast of the panel discussion will be available under the “Investors and News” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. For more information, please visit www.serestherapeutics.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227103007/en/
Investor and Media Contacts:
Windsor
Rwindsor@serestherapeutics.com
Source: Seres Therapeutics, Inc.
Eric Shaff will participate in a panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET.
The audio webcast of the panel discussion will be available under the 'Investors and News' section of Seres Therapeutics' website.
A replay of the presentation will be available approximately one hour after the event and will be archived for 21 days.
MCRB Rankings
#5388 Ranked by Stock Gains
MCRB Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About MCRB
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
